GETRONICS
22.10.2020 10:38:07 CEST | Business Wire | Press release
Today, Getronics announces a global rebrand marking the culmination of months of work following its acquisition in July 2020.
The rebrand will make Getronics stand out in a crowded market, where it is already a leader in managed workplace services (*Gartner Magic Quadrant February 2020).
Getronics delivers end-to-end capabilities designed to build digital experiences that drive exceptional business outcomes. Getronics has over 2000 customers, including Credit Agricole, Intersnack, and Inditex, as well as Ford Motors, which the company has served for over 35 years.
“Our company is on a mission to harness technology to transform our clients’ businesses. Our rebrand gives us the opportunity to re-energise our entire organisation. We have not needed to buy anything or create anything new from scratch to do this, it was all there within our business,” says Kenton Fine, Executive Chairman. “Now we have brought it all together, with a new brand and clarity to our offering. It is hugely exciting for us, our talented teams, and our fantastic customers. We know this will give us the fuel to propel our organic growth and to ensure that our customers thrive.”
The rebrand, led by Getronics senior leadership team – CTO, Harsha Gowda, COO and Head of Global Delivery, Rogier Bronsgeest, Group Transformation Director, Andre Ribbens, Getronics CFO, Mike Field, and recently appointed CCO, Tom Regent – will enable the Getronics team, customers, and partners together to harness the power of technology and to revolutionise the digital experience, thereby transforming businesses and advancing communities.
“We have reimagined what our digital future might look like, not just for the team at Getronics, but for all of our clients. Our previous identity did not stand out in the way we wanted. Because of our journey of expansion, we had some legacy brands which were not distinct and did not clarify our offering. Our new identity, of which all of our 4000 colleagues have had a sneak preview, makes Getronics distinctive,” concludes Getronics CTO, Harsah Gowda.
Getronics offers the following integrated services: Digital Workplace, Cloud Services, Smart Spaces, Business Applications, Security & Compliance, Field & On-Site Support, Service Desk, and Network Services. Getronics now has a striking visual identity, distinguishing it in the marketplace, establishing the group’s role in reimagining a digital future for business.
-ENDS-
Executive services
Getronics has defined its offering under 8 services:
● Digital Workplace – an always-on, intuitive experience
● Cloud Services – public, private and on-premises
● Smart Spaces – transforming work spaces into smart spaces
● Business Applications – applications that build trust and loyalty
● Security & Compliance – delivering trust and peace of mind
● Field & On-Site Support - any device, any time, anywhere
● Service Desk – get reassurance and peace of mind
● Network Services - connecting people and applications
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005507/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom